|
MechanismNMDA receptor antagonists [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date01 Jan 1958 |
100 Clinical Results associated with Procter & Gamble Australia Pty Ltd.
0 Patents (Medical) associated with Procter & Gamble Australia Pty Ltd.
100 Deals associated with Procter & Gamble Australia Pty Ltd.
100 Translational Medicine associated with Procter & Gamble Australia Pty Ltd.